Disease-modifying immunotherapy for the management of autoimmune diabetes.
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease that destroys the insulin-secreting beta-cells of the pancreas. It is now possible to predict those candidates that will progress to T1D before the full onset of the disease. Prevention of uncontrollable autoimmunity against beta-cells in therapies for T1D is mandatory to preserve the beta-cell mass. Therefore, immunomodulatory strategies directed to inhibiting the activity of self-reactive T cell clones as well as induction of regulatory T cells would be beneficial for prevention of T1D or recurrence of beta-cell autoimmunity against islet cell allografts.
Laboratorio de Fisiología y Biología Molecular (LFBM)-IFIBYNE-CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina.
Carla N
CN
Castro
Andres E
AE
Barcala Tabarrozi
Maria Antunica
MA
Noguerol
Ana C
AC
Liberman
Ricardo A
RA
Dewey
Eduardo
E
Arzt
Adrian E
AE
Morelli
Marcelo J
MJ
Perone
D000818:Animals; D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015551:Autoimmunity / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000503:physiopathology / Q000628:therapy*; D004195:Disease Models, Animal; D006801:Humans; D056747:Immunomodulation / Q000502:physiology; D007167:Immunotherapy / Q000379:methods* / Q000639:trends*; D050417:Insulin-Secreting Cells / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology
D018501:Antirheumatic Agents